Panel
Breakthroughs Reshaping Aging and Longevity | Global Conference 2026
- Therapeutics are projected to extend healthy human lifespan by 10 years and add five years by reversing age-related diseases, with RTR242 anticipated to restart autophagy in aged neurons and allow for measurable short-term clinical trial results.
- Industry consensus expects one approved therapeutic and four in human testing within the next five years, utilizing upstream mechanisms as proxies to navigate regulatory hurdles despite the absence of current major regulator approvals for an "aging" indication.
- Linkevity plans to advance a first-in-class necrosis-targeting drug into Phase 2 clinical trials through a partnership with the UK NHS, aiming to rapidly increase health span via a "Swiss Army knife" therapeutic.
- Continuous blood pressure monitoring is expected to achieve "practically clinical grade" accuracy within five percent based on a study of 400,000 participants, with Aura Health anticipating imminent regulatory approval and future reimbursement coverage once thresholds are met.
- A home-based brain protein card test, currently costing two to three thousand dollars in processing and mailing, is targeted to be priced under $150 and fully validated by this summer to serve as a "cholesterol test for the brain."
- Free software is expected to reduce Alzheimer's risk by 16% within six months through behavior change, supported by an NIH-funded trial on brain health education anticipated for acceptance at Nature Medicine.
- AI is forecasted to double daily operational productivity at Retro Biosciences, generate new proteins for research programs, and assist with accountability and education to address the difficulty of behavior change in prevention.
- The industry is expected to pivot funding toward multi-disease interventions rather than specific disease foci, with healthcare predictions and recommendations likely to be drastically altered by continuous personalized data collection over the next three to four years.
- Reproducibility gaps of five to ten percent in wearable data pose a risk of incorrect patient decisions, while the lack of clinically great accuracy in non-reimbursed tools may compel doctors to base decisions on imperfect information.
- The current healthcare system faces structural barriers due to missing reimbursement codes for Alzheimer's risk reduction, though two FDA-approved clinical trials for aging-related diseases suggest the regulatory system is preparing for future breakthroughs.
- Novel aging innovations are expected to follow a "biotech social contract" model, starting as expensive interventions in developed countries before becoming widely distributed, while capital constraints may impact excitement levels for the next five years.
- Potential rapid increases in lifespan from multi-disease therapeutics carry risks if the healthcare system is unprepared, although a window of economic opportunity similar to past productivity increases is anticipated from increased health span.